Alkylating agents and fludarabine for Waldenstrom's macroglobulinaemia

Evidence Summaries

Level of Evidence = C

In patients with Waldenstrom's macroglobulinaemia treated with fludarabine or CAP there may not be statistical difference in overall survival rate, but fludarabine may to be superior in terms of response rate and duration.

A Cochrane review 1 included 1 study with a total of 92 subjects. The effect of fludarabine was compared to the combination of cyclophosphamide (the alkylating agent), doxorubicin and prednisone (CAP) in patients with pretreated/relapsed WM. Compared to CAP, the Hazard ratio (HR) for deaths of treatment with fludarabine was estimated to be 1.04, with a standard error of 0.30 (95% CI 0.58 to 1.48) The mean difference of median survival time was -4.00 months, and 16.00 months for response duration in favour of fludarabine. The relative risks (RR) of response rate was 2.80 (95% CI 1.10 to 7.12).

Comment: The quality of evidence is downgraded by study quality (inadequate or unclear allocation concealment) and by imprecise results (few patients and wide confidence intervals).

References

1. Yang K, Tan J, Wu T. Alkylating agents for Waldenstrom's macroglobulinaemia. Cochrane Database Syst Rev 2009 Jan 21;(1):CD006719.  [PMID:19160296]


Copyright © 2017 Duodecim Medical Publications Limited.
Alkylating agents and fludarabine for Waldenstrom's macroglobulinaemia is a sample topic from the Evidence-Based Medicine Guidelines.

To view other topics, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Complete Product Information.